AMO (Advanced Medical Optics) closes Pfizer deal:
This article was originally published in Clinica
Executive Summary
Advanced Medical Optics (AMO) has completed the purchase of Pfizer's ophthalmic surgical business. Santa Ana, California-based AMO had agreed at the end of April this year to acquire the Pfizer unit in a $450m all-cash transaction (see Clinica No 1105, p 19). Through this deal, AMO's portfolio will be significantly boosted with the addition of Pfizer's CeeOn and Tecnis lines of intraocular lenses, its Healon family of viscoelastic products and the Baerveldt glaucoma shunt.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.